1. The Role of Measurable Residual Disease in AML

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. MRD in AML

4. Critical Questions for Assessing MRD in AML

5. Current Methods for Assessing MRD in AML

6. MRD Assessment in AML Is Not Yet Standardized

7. Is There a Preferred MRD Assay?

8. Standardization May Make MRD Assessment More Widely Available

9. Molecular Approaches to Assess MRD in AML

10. CyTOF to Measure MRD

11. Multiple Studies Demonstrate Prognostic Value of MRD in Younger Patients With AML

12. MRD Is an Independent Prognostic Factor

13. Molecular Monitoring of MRD in AML

14. Are 2 MRD Tests Better Than 1?

15. MRD Testing of Individual Genes vs Multigene Panels

16. What Is the Significance of Difficult-to-Clear Mutations?

17. Current State of MRD Testing in AML Expert Opinion

18. Effect of MRD on Transplant Outcomes

19. Using MRD in the Clinic Expert Guidance

20. Role of MRD Testing in Evaluating New AML Therapies

21. Converting MRD-Positive to MRD-Negative Can We Develop Therapies to Achieve This Goal?

22. Key Takeaways

23. Abbreviations

24. Abbreviations (cont)